
SUMO Protein Expression Platform



Noël Warren, Ph.D. and Abdul Haseeb, Ph.D.

LifeSensors Inc. 271 Great Valley Parkway Malvern PA 19355

610-644-8845 bd@lifesensors.com www.lifesensors.com





LifeSensors Inc.


- Leading Biotech in PROTAC/UPS Drug Discovery and protein expression R&D
- •~500 Product lines, PROTAC plates, ligases, DUBs, TUBEs affinity tools & Kits
- SUMO Protein Expression Systems
- PROTAC/UPS drug discovery, cell-based and biochemical HTS
- Collaborative and Independent Research





What is SUMO?

- SUMO, or <u>Small Ubiquitin-like modifier</u>, is a member of the ubiquitin family
- SUMO is not involved in targeting proteins for degradation
- Flexible N-terminal region followed by a compact ball-like Ubiquitin-like fold
- Nature designed SUMO to chaperone the proteins
- SUMO improves solubility due to hydrophillic shell and hydrophobic core







Benefits of the SUMO Platform


PROBLEMS

Unstable Protein or Low Expression

Specific N-terminus Required

Insolubility

High Cost of Goods



SOLUTIONS

SUMO-Chaperoning and Enhanced Expression


SUMO-Specific Processing

SUMO-Driven Folding and Solubility

Increased Quality and Quantity




SUMO Fusion Tag Platform








Protein Expression and Purification Process Using SUMO-tag







SUMOpro® fusion enhances expression and solubility in E. coli



Conditions: UN – Uninduced, IN – Induced, S – Soluble Fraction, IB – Inclusion Bodies

Marblestone et. al, Protein Sci. 2006 Jan;15(1):182-9



SUMOSTAR | Generating Post-Translationally Modified Proteins

Producing proteins that require post-translational modifications requires production in eukaryotic cells



PROBLEM

Eukaryotic cells have endogenous SUMO protease

SOLUTION

SUMOStar Protease










Insect

Mammalian


hSUMOstar Dramatically Enhances sPLA₂ Production & Secretion







hSUMOstar Dramatically Enhances Production of a Novel E3 ligase





Challenges with CAR-T and Gene Therapy

- Chimeric Antigen Receptors (CAR) are composed of scFV targeting tumor cells, membrane region and stimulatory domains
- RNA, Gene or vaccine therapies are similarly engineered proteins/receptors
- Lack of CAR expression, off-tumor effects, checkpoint blockade
- Augment CAR efficacy by enhancing quality and quantity of CARs






Role of SUMO in Enhancing CAR-T Efficacy

- Enhancing expression of under or non-expressed CARs
- Regulate level of expression by N-terminal rule
- On and off Switch for CARs
- Co-expression of tumor induced chemokines receptors
- CAS 9 expression





SUMO Expression in CAR-T / Gene Therapy Solution



BENEFITS


- Enhanced Expression
- Compartmentalization
- Improved Folding
- Improved Efficacy

TESENSORS I from genomics to proteomics



Lifesensors.com

mRNA Vaccines with SUMO-tag





Thank You

We are your partner in Protein Expression, CAR-T/Gene therapy and vaccine development

Contact Us!

Research & Product Inquiries R&D info@lifesensors.com 610-644-8845 (ext 339)

bd@lifesensors.com **Custom Service & Assays** BD 610-644-8845 (ext 310)



